Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.43−0.02 (-3.39%)
Close on Nov 18, 2026Market cap $249.06KP/E –Yield –
Virax Biolabs net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2026 it was -$5.02M. The highest annual figure on record is -$650.98K in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$5.02M | – |
| FY2025 | Mar 31, 2025 | -$6.06M | – |
| FY2024 | Mar 31, 2024 | -$6.73M | – |
| FY2023 | Mar 31, 2023 | -$5.46M | – |
| FY2022 | Mar 31, 2022 | -$1.71M | – |
| FY2021 | Mar 31, 2021 | -$650.98K | – |
See a number that looks wrong?